Siemens Healthineers Clinches ASTRO Award as Buyback Nears 3.43 Million Shares

Siemens Healthineers unveiled the Accela radiotherapy platform, allied with Truvian Health and kept buying back shares ahead of its 5 November Q4 report.

Siemens Healthineers is closing out its fiscal year with a flurry of product launches, partnership deals and share repurchases, even as investors train their attention on the group's fourth-quarter report due on 5 November.

The medical technology company's stock changed hands at EUR 38.13 on Tuesday, up 1.8%, giving it a market capitalisation of EUR 42.37 billion. A day earlier, the shares had settled at EUR 37.45.

ASTRO Recognises Accela Radiotherapy Platform

At the annual congress of the American Society for Radiation Oncology (ASTRO), Siemens Healthineers unveiled Accela, a radiotherapy system built on its NeoArc technology. The platform is designed to deliver stereotactic treatment within a single breath hold and to irradiate multiple targets in as little as 60 seconds. ASTRO also honoured the company with its Corporate Partner Award.

The launch came roughly a week before the ASTRO gathering, and it forms part of a broader push to sharpen the group's diagnostics and radiation therapy portfolio.

Truvian Alliance and D-Dimer Rollout Broaden Diagnostics

On the laboratory side, Siemens Healthineers struck a strategic alliance with US-based Truvian Health on 1 October to advance the TruVerus blood-testing platform. Under the arrangement, the German group will contribute development support, technical resources and manufacturing expertise, and will handle commercial advisory work. Both parties are also weighing further options for future diagnostic solutions and joint marketing. Financial terms were not disclosed.

Days earlier, on 29 September, the company launched its Innovance D-Dimer 2.0 assay worldwide. The test, which carries both CE marking and FDA 510(k) clearance, is used in laboratory assessment of patients with suspected venous thromboembolism. The D-Dimer rollout followed an earlier collaboration with Novo aimed at improving care for patients with MASLD and MASH through better access to non-invasive blood tests and earlier diagnosis.

Buyback Programme Grinds On

Siemens Healthineers continues to retire its own stock. In its 18th interim notification, the company said it repurchased 49,987 shares between 28 September and 4 October 2026. Since the programme began on 1 June 2026, the cumulative volume has reached 3,424,346 shares.

The repurchase framework allows for up to EUR 230 million in total, with transactions to be completed no later than 29 January 2027.

Deutsche Bank Stays on the Sidelines

Ahead of the earnings release, Deutsche Bank Research reiterated its "Hold" rating on the stock with a price target of EUR 39. Analyst Falko Friedrichs expects a solid final quarter and forecasts organic revenue growth of 6%.

Before the 5 November report, which will cover both the fourth quarter and the full 2026 fiscal year, Siemens Healthineers will make several appearances on the conference circuit. From Wednesday through 9 October, it will present at EUROSPINE 2026 in Gothenburg, Sweden. Its own Executive Summit 2026 in Frankfurt am Main follows on 19 and 20 October.